<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Cold Spring Harb Mol Case Stud</journal-id>
<journal-id journal-id-type="iso-abbrev">Cold Spring Harb Mol Case Stud</journal-id>
<journal-id journal-id-type="hwp">cshmcs</journal-id>
<journal-id journal-id-type="pmc">cshmcs</journal-id>
<journal-id journal-id-type="publisher-id">cshmcs</journal-id>
<journal-title-group>
<journal-title>Cold Spring Harbor Molecular Case Studies</journal-title>
</journal-title-group>
<issn pub-type="epub">2373-2873</issn>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory Press</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29162653</article-id>
<article-id pub-id-type="pmc">5701309</article-id>
<article-id pub-id-type="doi">10.1101/mcs.a002097</article-id>
<article-id pub-id-type="medline">TanakaMCS002097</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Report</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>De novo variants in <italic>EBF3</italic> are associated with hypotonia, developmental delay, intellectual disability, and autism</article-title>
<alt-title alt-title-type="left-running"><italic>EBF3</italic> variants in patients with hypotonia, developmental delay, intellectual disability, and autism</alt-title>
<alt-title alt-title-type="right-running"><italic>EBF3</italic> variants in patients with hypotonia, developmental delay, intellectual disability, and autism</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Tanaka</surname>
<given-names>Akemi J.</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cho</surname>
<given-names>Megan T.</given-names>
</name>
<xref ref-type="aff" rid="af2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Willaert</surname>
<given-names>Rebecca</given-names>
</name>
<xref ref-type="aff" rid="af2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Retterer</surname>
<given-names>Kyle</given-names>
</name>
<xref ref-type="aff" rid="af2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zarate</surname>
<given-names>Yuri A.</given-names>
</name>
<xref ref-type="aff" rid="af3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bosanko</surname>
<given-names>Katie</given-names>
</name>
<xref ref-type="aff" rid="af3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stefans</surname>
<given-names>Vikki</given-names>
</name>
<xref ref-type="aff" rid="af4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Oishi</surname>
<given-names>Kimihiko</given-names>
</name>
<xref ref-type="aff" rid="af5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Williamson</surname>
<given-names>Amy</given-names>
</name>
<xref ref-type="aff" rid="af5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wilson</surname>
<given-names>Golder N.</given-names>
</name>
<xref ref-type="aff" rid="af6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Basinger</surname>
<given-names>Alice</given-names>
</name>
<xref ref-type="aff" rid="af7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Barbaro-Dieber</surname>
<given-names>Tina</given-names>
</name>
<xref ref-type="aff" rid="af7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ortega</surname>
<given-names>Lucia</given-names>
</name>
<xref ref-type="aff" rid="af7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sorrentino</surname>
<given-names>Susanna</given-names>
</name>
<xref ref-type="aff" rid="af8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gabriel</surname>
<given-names>Melissa K.</given-names>
</name>
<xref ref-type="aff" rid="af9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Anderson</surname>
<given-names>Ilse J.</given-names>
</name>
<xref ref-type="aff" rid="af10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sacoto</surname>
<given-names>Maria J. Guillen</given-names>
</name>
<xref ref-type="aff" rid="af2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schnur</surname>
<given-names>Rhonda E.</given-names>
</name>
<xref ref-type="aff" rid="af2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chung</surname>
<given-names>Wendy K.</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
<xref ref-type="aff" rid="af11">11</xref>
</contrib>
</contrib-group>
<aff id="af1"><label>1</label>Department of Pediatrics, Columbia University Medical Center, New York, New York 10032, USA;</aff>
<aff id="af2"><label>2</label>GeneDx, Gaithersburg, Maryland 20877, USA;</aff>
<aff id="af3"><label>3</label>Section of Genetics and Metabolism, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA;</aff>
<aff id="af4"><label>4</label>Departments of Pediatrics and Physical Medicine and Rehabilitation, Arkansas Children's Hospital, Little Rock, Arkansas 72202, USA;</aff>
<aff id="af5"><label>5</label>Department of Genetics and Genomic Sciences, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA;</aff>
<aff id="af6"><label>6</label>KinderGenome Genetics, Medical City Hospital Dallas, Dallas, Texas 75230, USA, and Department of Pediatrics, Texas Tech University Health Science Center, Lubbock, Texas 79430, USA;</aff>
<aff id="af7"><label>7</label>Cook Children's Genetics, Fort Worth, Texas 76102, USA;</aff>
<aff id="af8"><label>8</label>Department of Genetics and Metabolism, Valley Children's Hospital, Madera, California 93636, USA;</aff>
<aff id="af9"><label>9</label>Children's Hospital of Los Angeles, Los Angeles, California 90027, USA;</aff>
<aff id="af10"><label>10</label>Department of Genetics, University of Tennessee, Knoxville, Tennessee 37996, USA;</aff>
<aff id="af11"><label>11</label>Department of Medicine, Columbia University Medical Center, New York, New York 10032, USA</aff>
<author-notes>
<corresp>Corresponding author: <email>wkc15@columbia.edu</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>11</month>
<year>2017</year>
</pub-date>
<volume>3</volume>
<issue>6</issue>
<elocation-id>a002097</elocation-id>
<history>
<date date-type="received">
<day>2</day>
<month>5</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>5</day>
<month>7</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>
<ext-link ext-link-type="uri" xlink:href="http://www.molecularcasestudies.cshlp.org/site/misc/terms.xhtml">© 2017 Tanaka et al.; Published by Cold Spring Harbor Laboratory Press</ext-link>
</copyright-statement>
<copyright-year>2017</copyright-year>
<license xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution-NonCommercial License</ext-link>, which permits reuse and redistribution, except for commercial purposes, provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="TanakaMCS002097.pdf"></self-uri>
<abstract>
<p>Using whole-exome sequencing, we identified seven unrelated individuals with global developmental delay, hypotonia, dysmorphic facial features, and an increased frequency of short stature, ataxia, and autism with de novo heterozygous frameshift, nonsense, splice, and missense variants in the <italic>Early B-cell Transcription Factor Family Member 3</italic> (<italic>EBF3</italic>) gene. EBF3 is a member of the collier/olfactory-1/early B-cell factor (COE) family of proteins, which are required for central nervous system (CNS) development. COE proteins are highly evolutionarily conserved and regulate neuronal specification, migration, axon guidance, and dendritogenesis during development and are essential for maintaining neuronal identity in adult neurons. Haploinsufficiency of <italic>EBF3</italic> may affect brain development and function, resulting in developmental delay, intellectual disability, and behavioral differences observed in individuals with a deleterious variant in <italic>EBF3</italic>.</p>
</abstract>
<kwd-group>
<kwd>autism</kwd>
<kwd>central hypotonia</kwd>
<kwd>intellectual disability, mild</kwd>
<kwd>moderate global developmental delay</kwd>
<kwd>neurogenic bladder</kwd>
</kwd-group>
<funding-group>
<award-group id="funding-1">
<funding-source>
<institution-wrap>
<institution>Simons Foundation </institution>
<institution-id institution-id-type="open-funder-registry">10.13039/100000893</institution-id>
</institution-wrap>
</funding-source>
</award-group>
</funding-group>
<counts>
<page-count count="12"></page-count>
</counts>
</article-meta>
</front>
<body><sec id="s1" sec-type="introduction"><title>INTRODUCTION</title><p>Early B-cell factor 3 (<italic>EBF3</italic>) is located on Chromosome 10q26.3 and is a member of the <bold>c</bold>ollier/olfactory-1/EBF (COE) family of transcription factors required for the development and differentiation of various cell types across species, from planarians to humans (<xref ref-type="bibr" rid="TANAKAMCS002097C2">Bu and Su 2003</xref>; <xref ref-type="bibr" rid="TANAKAMCS002097C23">Siponen et al. 2010</xref>; <xref ref-type="bibr" rid="TANAKAMCS002097C7">Cowles et al. 2014</xref>). The COE family of proteins has low sequence similarity to other protein families, but all COE proteins share a conserved amino-terminal DNA-binding domain with a unique zinc-finger binding motif, an immunogolubulin Ig-like, plexins, transcription factors (IPT/TIG) domain, and an atypical helix–loop–helix domain with a dimerization motif (<xref ref-type="fig" rid="TANAKAMCS002097F1">Fig. 1</xref>A; <xref ref-type="bibr" rid="TANAKAMCS002097C18">Liberg et al. 2002</xref>; <xref ref-type="bibr" rid="TANAKAMCS002097C23">Siponen et al. 2010</xref>). COE transcription factors play an important role in the nervous system and brain development, including neuronal differentiation, migration, axon guidance, and dendritogenesis, and are also necessary for the specification and maintenance of neuronal identity in adult neurons (<xref ref-type="bibr" rid="TANAKAMCS002097C29">Wang et al. 2004</xref>). Mice and humans have four COE paralogs, EBF1-4 (<xref ref-type="bibr" rid="TANAKAMCS002097C9">Daburon et al. 2008</xref>), which may have complementary and redundant roles (<xref ref-type="bibr" rid="TANAKAMCS002097C10">Dubois and Vincent 2001</xref>; <xref ref-type="bibr" rid="TANAKAMCS002097C18">Liberg et al. 2002</xref>). Among the COE paralogs, <italic>EBF3</italic> is highly expressed throughout the brain during development in mice and humans (<xref ref-type="bibr" rid="TANAKAMCS002097C30">Zhao et al. 2006</xref>; <xref ref-type="bibr" rid="TANAKAMCS002097C26">Tao et al. 2015</xref>) and is required for the migration of Cajal–Retzius cells during corticogenesis and the terminal differentiation and maintenance of specialized neurons in the adult brain (<xref ref-type="bibr" rid="TANAKAMCS002097C10">Dubois and Vincent 2001</xref>; <xref ref-type="bibr" rid="TANAKAMCS002097C14">Garcia-Dominguez et al. 2003</xref>; <xref ref-type="bibr" rid="TANAKAMCS002097C27">Thuret et al. 2004</xref>; <xref ref-type="bibr" rid="TANAKAMCS002097C4">Chiara et al. 2012</xref>). <italic>EBF3</italic> also acts as a putative tumor suppressor by activating cell cycle arrest and inducing apoptosis (<xref ref-type="bibr" rid="TANAKAMCS002097C30">Zhao et al. 2006</xref>).</p><fig id="TANAKAMCS002097F1" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>(<italic>A</italic>) De novo variants in <italic>EBF3</italic>. Missense variants in EBF3 (NP_001005463.1) are shown <italic>above</italic> the protein diagram and likely gene-disrupting mutations are <italic>below</italic>. The variants identified in our patients are in black and ones in individuals reported by others are in gray. COE1, collier/olfactory-1/EBF. DBD, DNA-binding domain. IPT, Ig-like, plexins, transcription factors domain. HLHLH, atypical helix–loop–helix (HLH) domain. TAD, transactivation domain. Light blue region in COE1 DBD represents unique zinc finger binding motif. (<italic>B</italic>) Sequence alignment of EBF3 and its homologs across species with residues mutated in our patients in red. Macmu, rhesus monkey, Xentr, <italic>Xenopus tropicalis</italic>, Danre, zebrafish, Drome, <italic>Drosophila melanogaster</italic>, Tribr, parasitic roundworm.</p></caption><graphic xlink:href="TanakaMCS002097_F1"></graphic></fig><p>Previous reports have identified approximately 100 patients with terminal 10q deletions, who demonstrate a wide range of clinical features frequently including delayed development, intellectual disability, and craniosynostosis (<xref ref-type="bibr" rid="TANAKAMCS002097C11">Faria et al. 2015</xref>). <italic>EBF3</italic> is within a shared deletion of Chromosome 10q26.3 in many of these patients. Four recent reports identified a total of 20 unrelated individuals and two siblings who have de novo variants in <italic>EBF3</italic> and a distinct neurodevelopmental syndrome (<xref ref-type="bibr" rid="TANAKAMCS002097C1">Blackburn et al. 2017</xref>; <xref ref-type="bibr" rid="TANAKAMCS002097C3">Chao et al. 2017</xref>; <xref ref-type="bibr" rid="TANAKAMCS002097C15">Harms et al. 2017</xref>; <xref ref-type="bibr" rid="TANAKAMCS002097C24">Sleven et al. 2017</xref>). Here we add further evidence for the role of <italic>EBF3</italic> in brain development and expand the phenotype of this syndrome caused by pathogenic variants in <italic>EBF3</italic>. We describe seven unrelated individuals who have heterozygous de novo variants in <italic>EBF3</italic> that are predicted to be deleterious and who share common features of global developmental delay, intellectual disability (ID), hypotonia, and dysmorphic features.</p></sec><sec id="s2" sec-type="results"><title>RESULTS</title><p>Clinical WES was performed on 8057 individuals with developmental delay and/or intellectual disabilities in a single clinical laboratory. In 11 affected individuals from 11 unrelated families, we identified de novo variants in <italic>EBF3</italic> as potentially causative for the neurodevelopmental phenotype. Candidate disease-causing variants in the <italic>EBF3</italic> gene were confirmed by Sanger sequencing to be de novo. Only seven of the 11 de novo predicted pathogenic variants we observed are reported in the manuscript based on permission of the referring physicians to report the results. Some of the patients who were diagnosed were included in other publications and were therefore not included in this series. The variants include one nonsense, two frameshift deletions, one splice, and three missense variants (<xref ref-type="fig" rid="TANAKAMCS002097F1">Fig. 1</xref>). All seven variants identified are novel, located in highly evolutionarily conserved regions across species, and predicted to be deleterious by SIFT (<uri xlink:href="http://sift.jcvi.org/">http://sift.jcvi.org/</uri>), CADD (<uri xlink:href="http://cadd.gs.washington.edu/">http://cadd.gs.washington.edu/</uri>), MetaSVM (<uri xlink:href="https://omictools.com/meta-svm-tool">https://omictools.com/meta-svm-tool</uri>), and MutationTaster (<uri xlink:href="http://www.mutationtaster.org/">http://www.mutationtaster.org/</uri>) (<xref ref-type="table" rid="TANAKAMCS002097TB1">Table 1</xref>; <xref ref-type="fig" rid="TANAKAMCS002097F1">Fig. 1</xref>B). No likely gene-disrupting <italic>EBF3</italic> variants were detected in ExAC (<uri xlink:href="http://exac.broadinstitute.org/">http://exac.broadinstitute.org/</uri>), 1000 Genomes (<uri xlink:href="http://www.internationalgenome.org/">http://www.internationalgenome.org/</uri>), ESP (<uri xlink:href="http://evs.gs.washington.edu/EVS/">http://evs.gs.washington.edu/EVS/</uri>), or our own internal database of 24,709 exomes of unaffected parents of children referred for testing. Additionally, the non-TCGA ExAC v0.3.1 gene tolerance scores of mis<italic>Z</italic> = 4.89 and <italic>p</italic>(LI) = 1.00 indicate that the gene is highly constrained against both missense and loss-of-function (LOF) variation across humans, respectively. Using TADA (<xref ref-type="bibr" rid="TANAKAMCS002097C16">He et al. 2013</xref>) default parameters for ID/DD and the expected mutation rate of 2.331847 × 10<sup>−05</sup> for missense variants and 8.693607 × 10<sup>−07</sup> for LOF variants (<xref ref-type="bibr" rid="TANAKAMCS002097C21">Samocha et al. 2014</xref>), we calculate a false-discovery corrected <italic>q</italic>-value of 3.84 × 10<sup>−08</sup> for observing six de novo LOF and five de novo missense variants in <italic>EFB3</italic> within our cohort.</p><table-wrap id="TANAKAMCS002097TB1" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Predicted pathogenicity and allele frequencies of <italic>EBF3</italic> variants</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Patient</th><th align="center" colspan="1" rowspan="1">Chromosome 10 coordinates (GRCh37/hg19)</th><th align="center" colspan="1" rowspan="1">Nucleotide change</th><th align="center" colspan="1" rowspan="1">Amino acid change</th><th align="center" colspan="1" rowspan="1">SIFT</th><th align="center" colspan="1" rowspan="1">PROVEAN</th><th align="center" colspan="1" rowspan="1">PolyPhen2</th><th align="center" colspan="1" rowspan="1">Mutation-Taster</th><th align="center" colspan="1" rowspan="1">CADD Phred</th><th align="center" colspan="1" rowspan="1">Allele frequency in ExAC and GeneDx database of 49,418 alleles</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">131761731:T&gt;G</td><td colspan="1" rowspan="1">c.191A&gt;C</td><td colspan="1" rowspan="1">K64T</td><td colspan="1" rowspan="1">Damaging</td><td colspan="1" rowspan="1">Deleterious (−4.3)</td><td colspan="1" rowspan="1">Probably damaging (0.99)</td><td colspan="1" rowspan="1">Disease-causing</td><td colspan="1" rowspan="1">19.3</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">131761679:C&gt;-</td><td colspan="1" rowspan="1">c.244delG</td><td colspan="1" rowspan="1">V82WfsX50</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">131757212:G&gt;T</td><td colspan="1" rowspan="1">c.471C&gt;A</td><td colspan="1" rowspan="1">H157Q</td><td colspan="1" rowspan="1">Damaging</td><td colspan="1" rowspan="1">Deleterious (−6.2)</td><td colspan="1" rowspan="1">Possibly damaging (0.9)</td><td colspan="1" rowspan="1">Disease-causing</td><td colspan="1" rowspan="1">18.3</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">131755591:C&gt;T</td><td colspan="1" rowspan="1">c.486-1G&gt;A</td><td colspan="1" rowspan="1">IVS5-1G&gt;A</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">Disease-causing</td><td colspan="1" rowspan="1">32</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">131676052:G&gt;A</td><td colspan="1" rowspan="1">c.616C&gt;T</td><td colspan="1" rowspan="1">R206X</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">Automatic disease-causing</td><td colspan="1" rowspan="1">18.1</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">131676042:C&gt;T</td><td colspan="1" rowspan="1">c.626G&gt;A</td><td colspan="1" rowspan="1">R209Q</td><td colspan="1" rowspan="1">Damaging</td><td colspan="1" rowspan="1">Deleterious (−3.4)</td><td colspan="1" rowspan="1">Possibly damaging (0.9)</td><td colspan="1" rowspan="1">Disease-causing</td><td colspan="1" rowspan="1">20.4</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">131639239GTACT GCTGGGGA&gt;-</td><td colspan="1" rowspan="1">c.1402_1414d eI13</td><td colspan="1" rowspan="1">T464PfsX10</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">0</td></tr></tbody></table></table-wrap><sec id="s2a"><title>Clinical Presentation and Family History</title><p>The seven unrelated individuals include five females and two males who range in age from 1 to 24 yr (see <xref ref-type="table" rid="TANAKAMCS002097TB2">Table 2</xref>; <ext-link ext-link-type="uri" xlink:href="http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002097/-/DC1">Supplemental Table S1</ext-link>). They all share similar clinical features of global developmental delay or intellectual disabilities and of hypotonia or rarely hypertonia. Four of the five individuals over the age of three were verbal. Many of the individuals also demonstrated autism and/or attention deficit hyperactivity disorder (ADHD) and behavioral differences including poor eye contact, self-injurious behavior, or altered pain sensitivity. The only adult in our series also had tics and auditory and visual hallucinations. Notably, none had seizures nor were there consistent brain malformations, and head circumferences ranged from relatively small to relatively large. Most of the individuals have distinctive physical features including triangular face, synophrys, small ears, highly arched palate and crowded teeth, and single palmar crease (<xref ref-type="fig" rid="TANAKAMCS002097F2">Fig. 2</xref>). All of our patients have moderate-to-severe neurodevelopmental impairment. Approximately half of the patients have autism and half of them have motor coordination problems including ataxia. Six of the seven individuals had neurological findings, including coordination issues, insensitivity to pain, muscle weakness, and ataxic gait. Abnormal brain MRIs were observed, including vermis hypoplasia, delayed myelination, or irregular frontal cerebral white matter and protuberance of optic papillae in three separate patients (<xref ref-type="fig" rid="TANAKAMCS002097F3">Fig. 3</xref>). Additional notable features in the minority of individuals included altered pain sensitivity and sleep issues. Ophthalmologic problems were common and included strabismus, esotropia, amblyopia, and delayed visual maturation. Short stature was common and height was in the lower quartile for all but one individual. Skeletal abnormalities were less common and included pectus excavatum, severe scoliosis, pronation, and hallux valgus. Genitourinary issues included microphallus in two, urinary tract infections and hydronephrosis in one, and unilateral renal duplication, and vesicoureteral reflux in another.</p><fig id="TANAKAMCS002097F2" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Photographs of patients with de novo variants in EBF3. (<italic>A</italic>) Patient 4 at 11 yr old. Note triangular face. (<italic>B,B</italic>′) Patient 5 at 11 yr old. Note round, mildly coarse face, mild maxillary hypoplasia and prominent mandible, highly arched eyebrows and synophrys, long palpebral fissures, short philtrum and thin upper lip, and anteverted nares.</p></caption><graphic xlink:href="TanakaMCS002097_F2"></graphic></fig><fig id="TANAKAMCS002097F3" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Brain imaging data of individual with EBF3 variant. (<italic>A</italic>,<italic>B</italic>) Sagittal and (<italic>A</italic>′,<italic>B</italic>′) axial images of Individual 4 at 9 mo (<italic>A</italic>,<italic>A</italic>′) and 9 yr (<italic>B</italic>,<italic>B</italic>′) of age show a mild hypoplasia of the cerebellar vermis, mildly dysplastic corpus callosum, and small pericallosal lipoma without evidence of significant progression.</p></caption><graphic xlink:href="TanakaMCS002097_F3"></graphic></fig></sec></sec><sec id="s3" sec-type="discussion"><title>DISCUSSION</title><p>We add to the emerging evidence for a clinical syndrome characterized by global developmental delay/intellectual disability, autism, hypotonia, and dysmorphic features due to heterozygous de novo predicted pathogenic variants in <italic>EBF3</italic>. Although not observed in all patients, ataxia/coordination problems, strabismus, skeletal abnormalities, short stature, and urogenital anomalies are also common features. The allelic spectrum we observed includes several likely gene-disrupting variants: one nonsense, two frameshift, and one splice variant. In addition there are three de novo missense variants, (p.(Lys64Thr), p.(His157Gln), and p.(Arg209Gln), which are all in the COE1 DNA-binding domain (DBD) (<xref ref-type="fig" rid="TANAKAMCS002097F4">Fig. 4</xref>; <xref ref-type="bibr" rid="TANAKAMCS002097C23">Siponen et al. 2010</xref>). The p.(His157Gln) mutation lies in the “EBF zinc knuckle” motif located in the COE1 DBD, which is crucial for zinc coordination and positioning of residues for DNA binding. The splice site variant, c.486-1G&gt;A, may also cause the loss of the splice acceptor site and induce skipping of exon 6, which encodes the conserved zinc knuckle motif in the COE1 DBD. Molecular modeling of EBF3 mutations at the zinc knuckle has demonstrated decreased DNA affinity resulting in aberrant DNA binding (<xref ref-type="bibr" rid="TANAKAMCS002097C1">Blackburn et al. 2017</xref>). Altered expression or binding of <italic>EBF3</italic> is likely responsible for the predominance of neurological symptoms seen in our patients. Mutations in <italic>Ebf3</italic> in the brains of adult mice result in a modest reduction in olfactory bulb size and defective olfactory axon projections to the dorsal and lateral surfaces of the olfactory bulb (<xref ref-type="bibr" rid="TANAKAMCS002097C29">Wang et al. 2004</xref>). <xref ref-type="bibr" rid="TANAKAMCS002097C17">Jin et al. (2014)</xref> further determined that <italic>Ebf3</italic> is strongly expressed in the midbrain, cerebellum, and the mantle layer of the spinal cord and generated <italic>Ebf3</italic>-deficient mice that died from respiratory failure due to dysfunctional diaphragm relaxation within 12 h following birth (P0.5) (<xref ref-type="bibr" rid="TANAKAMCS002097C17">Jin et al. 2014</xref>). Detailed investigation of the brains of <italic>Ebf3</italic> mutant mice and the generation of conditional knockout mice will likely reveal additional functions for <italic>EBF3</italic> in regulating the genetic programs involved in developing and maintaining neuronal function. In humans, reports of deletions of a common 1-Mb region on 10q26.3 including <italic>EBF3</italic> have been associated with severe neurodevelopmental delay and intellectual disability (<xref ref-type="bibr" rid="TANAKAMCS002097C11">Faria et al. 2015</xref>), although additional genes in the interval including <italic>MGMT</italic>, <italic>PPP2R2D</italic>, and <italic>BNIP3</italic> may also contribute to the phenotype in 10q26.3 deletion patients.</p><fig id="TANAKAMCS002097F4" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Deleterious de novo missense variants in the EBF DNA-binding domain (DBD). (<italic>A</italic>) Structural representation of the EBF DBD based on original 3D representation of EBF3 in <xref ref-type="bibr" rid="TANAKAMCS002097C23">Siponen et al. (2010)</xref> with the three residues affected by missense variants in our patients in green. The H157 residue is part of the EBF zinc knuckle (box), which coordinates EBF binding to DNA. (<italic>B</italic>) Top view of residues involved in zinc coordination are indicated.</p></caption><graphic xlink:href="TanakaMCS002097_F4"></graphic></fig><p>Four groups independently reported a total of 22 unique individuals who have <italic>EBF3</italic> nonsense, missense, and splice variants with clinical features shared by our patients (<xref ref-type="bibr" rid="TANAKAMCS002097C1">Blackburn et al. 2017</xref>; <xref ref-type="bibr" rid="TANAKAMCS002097C3">Chao et al. 2017</xref>; <xref ref-type="bibr" rid="TANAKAMCS002097C15">Harms et al. 2017</xref>; <xref ref-type="bibr" rid="TANAKAMCS002097C24">Sleven et al. 2017</xref>), including one individual with a diagnosis of ADHD (<xref ref-type="bibr" rid="TANAKAMCS002097C15">Harms et al. 2017</xref>), three with autistic-like behavior (<xref ref-type="bibr" rid="TANAKAMCS002097C24">Sleven et al. 2017</xref>), and one with a family history of ADHD and sleep problems (<xref ref-type="bibr" rid="TANAKAMCS002097C1">Blackburn et al. 2017</xref>). Several of our patients exhibited behavioral differences including repetitive hair pulling, self-injurious face rubbing, and lack of eye contact or social smile. Three of the individuals with autism in our study also had abnormal brain imaging, including vermis hypoplasia, delayed myelination, and small structural defects in the right temporal lobe (Patient 5) and optic papillae (Patient 6) (<xref ref-type="table" rid="TANAKAMCS002097TB2">Table 2</xref>; <ext-link ext-link-type="uri" xlink:href="http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002097/-/DC1">Supplemental Table S1</ext-link>). We provide additional evidence for the role of <italic>EBF3</italic> in brain development and hypothesize that decreased or aberrant binding of EBF3 to its targets lead to abnormal gene regulation during brain development and may be responsible for the global developmental delay and altered brain function consistently observed in individuals with mutations in <italic>EBF3</italic>. We suggest the variants we describe result in loss of function and haploinsufficiency of EBF3 and are a cause of autism and intellectual disabilities.</p><table-wrap id="TANAKAMCS002097TB2" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Clinical details of patients with <italic>EBF3</italic> variants</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Patient</th><th align="center" colspan="1" rowspan="1">Age</th><th align="center" colspan="1" rowspan="1">Sex</th><th align="center" colspan="1" rowspan="1">Variant</th><th align="center" colspan="1" rowspan="1">Age at sitting</th><th align="center" colspan="1" rowspan="1">Age at walking</th><th align="center" colspan="1" rowspan="1">Verbal skills</th><th align="center" colspan="1" rowspan="1">Muscle tone</th><th align="center" colspan="1" rowspan="1">Additional neurological findings</th><th align="center" colspan="1" rowspan="1">Vision</th><th align="center" colspan="1" rowspan="1">Seizure</th><th align="center" colspan="1" rowspan="1">Abnormal behavior</th><th align="center" colspan="1" rowspan="1">ADD/ADHD</th><th align="center" colspan="1" rowspan="1">Brain MRI</th><th align="center" colspan="1" rowspan="1">Renal or urogenital issues</th><th align="center" colspan="1" rowspan="1">Gl</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">30 mo</td><td colspan="1" rowspan="1">M</td><td colspan="1" rowspan="1">c.191A&gt;C p.Lys64Thr;</td><td colspan="1" rowspan="1">18 mo</td><td colspan="1" rowspan="1">Cannot walk on own, able to stand without support</td><td colspan="1" rowspan="1">Nonverbal; able to communicate with sign language</td><td colspan="1" rowspan="1">Hypotonia</td><td colspan="1" rowspan="1">Coordination issues; insensitivity/decreased sensitivity to pain; fine and gross motor difficulties</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">Moderate eye contact; did not smile until 11 mo old</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">Small penis</td><td colspan="1" rowspan="1">History of poor weight gain</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">24 yo</td><td colspan="1" rowspan="1">F</td><td colspan="1" rowspan="1">c.244delG, p.Val82TrpfsX50</td><td colspan="1" rowspan="1">9 mo</td><td colspan="1" rowspan="1">2 yo</td><td colspan="1" rowspan="1">Talked at 9 mo; Full sentences, normal mild articulation problems</td><td colspan="1" rowspan="1">Hypotonia</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">Strabismus, surgically repaired</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">Autistic features; tics; hallucinations (auditory and visual); emotional fragility; self- injurious behavior; hair pulling</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">Normal</td><td colspan="1" rowspan="1">Normal</td><td colspan="1" rowspan="1">Normal</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">10 yo</td><td colspan="1" rowspan="1">F</td><td colspan="1" rowspan="1">c.471C&gt;A, p.His157Gln</td><td colspan="1" rowspan="1">1 yo</td><td colspan="1" rowspan="1">3 yo</td><td colspan="1" rowspan="1">Talked at 5 yo; normal vocabulary for age with articulation differences</td><td colspan="1" rowspan="1">Hypotonia</td><td colspan="1" rowspan="1">Fine motor difficulties; decreased pain sensitivity</td><td colspan="1" rowspan="1">Strabismus</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">Autism; tantrums and melt-downs</td><td colspan="1" rowspan="1">Hyperactivity</td><td colspan="1" rowspan="1">Normal</td><td colspan="1" rowspan="1">Vesicostomy surgery for vesicoureteral reflux and poor bladder emptying; left renal duplication; urine retention with neurogenic bladder, needs nocturnal catheter</td><td colspan="1" rowspan="1">Normal</td></tr><tr><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">11 yo</td><td colspan="1" rowspan="1">F</td><td colspan="1" rowspan="1">c.486-1G&gt;A, IVS5-1G&gt;A</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">Cannot walk on own, needs assistance or walker</td><td colspan="1" rowspan="1">Nonverbal, no words but hums tunes</td><td colspan="1" rowspan="1">Hypotonia</td><td colspan="1" rowspan="1">Muscle weakness; ataxic gait</td><td colspan="1" rowspan="1">Strabismus, surgically repaired</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">Autistic features; rubs face on hard objects to point of bruising</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">Vermis hypoplasia</td><td colspan="1" rowspan="1">Normal</td><td colspan="1" rowspan="1">Constipation; requires G- tube feeds; takes only baby foods orally</td></tr><tr><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">11 yo</td><td colspan="1" rowspan="1">F</td><td colspan="1" rowspan="1">c.616C&gt;T, p.Arg206X</td><td colspan="1" rowspan="1">4 mo</td><td colspan="1" rowspan="1">14 mo; Wears leg braces</td><td colspan="1" rowspan="1">Talked at 10 mo; Articulation defect</td><td colspan="1" rowspan="1">Hypotonia</td><td colspan="1" rowspan="1">Hyporeflexia or difficult to elicit DTRs; mild dysmetria and gait incoordination; inconsistent sensory exam, mild proximal muscle weakness</td><td colspan="1" rowspan="1">Refractive error</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">Autism; oppositional defiant disorder</td><td colspan="1" rowspan="1">ADHD</td><td colspan="1" rowspan="1">Small schizencephalic cleft in right temporal lobe and delayed myelination at 2 yo, later resolved</td><td colspan="1" rowspan="1">History of UTIs and hydronephrosis, resolved with growth</td><td colspan="1" rowspan="1">Excess weight gain, BMI 33.5 (≫95th percentile)</td></tr><tr><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">15 mo</td><td colspan="1" rowspan="1">M</td><td colspan="1" rowspan="1">c.626G&gt;A p.Arg209Gln</td><td colspan="1" rowspan="1">9 mo</td><td colspan="1" rowspan="1">Cannot walk at 12 mo</td><td colspan="1" rowspan="1">Babbling at 8 mo; No clear first words at 12 mo</td><td colspan="1" rowspan="1">Hypotonia</td><td colspan="1" rowspan="1">Muscle weakness; ataxic gait</td><td colspan="1" rowspan="1">Strabismus</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">Some eye contact, but no social smile</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">Curvilinear tract-like signal abnormality in left frontal cerebral white matter; protuberance of right optic papillae</td><td colspan="1" rowspan="1">Small penis; testes high in scrotum</td><td colspan="1" rowspan="1">Normal</td></tr><tr><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">4 yo</td><td colspan="1" rowspan="1">F</td><td colspan="1" rowspan="1">c.1402_1414del13, p.Thr464ProfsX10</td><td colspan="1" rowspan="1">8 mo</td><td colspan="1" rowspan="1">2 yo</td><td colspan="1" rowspan="1">Talked at 2 yo; Speaking in full sentences at 4 yo</td><td colspan="1" rowspan="1">Hypertonia in hips</td><td colspan="1" rowspan="1">Muscle weakness; ataxic gait</td><td colspan="1" rowspan="1">Normal</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">Oral fixation, awakens at night</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">Normal</td><td colspan="1" rowspan="1">Recurrent urinary tract infections</td><td colspan="1" rowspan="1">Normal</td></tr></tbody></table><table-wrap-foot><fn><p>See <ext-link ext-link-type="uri" xlink:href="http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002097/-/DC1">Supplemental Table S1</ext-link> for additional details of clinical presentations.</p></fn><fn><p>yo, years old; ADD, attention deficit disorder; ADHD attention deficit hyperactivity disorder; N/A, not available.</p></fn></table-wrap-foot></table-wrap><p>The missense variants identified in the individuals in this study are all amino acid substitutions that result in a change in charge, which may alter the DNA binding of EBF3 to its binding partners, including aristaless related homeobox (<italic>ARX</italic>) (<xref ref-type="bibr" rid="TANAKAMCS002097C12">Friocourt and Parnavelas 2011</xref>; <xref ref-type="bibr" rid="TANAKAMCS002097C20">Olivetti et al. 2014</xref>). Genes regulated by ARX include ones that are involved in or have been linked to CNS disorders with intellectual disability and autism (<xref ref-type="bibr" rid="TANAKAMCS002097C13">Fulp et al. 2008</xref>). <italic>ARX</italic> regulates the transcription of genes involved in cell differentiation, migration, and maturation during interneuron development in the brain and has been shown to repress <italic>EBF3</italic> and its putative tumor-suppressing properties, such as cell cycle arrest and apoptosis (<xref ref-type="bibr" rid="TANAKAMCS002097C13">Fulp et al. 2008</xref>; <xref ref-type="bibr" rid="TANAKAMCS002097C20">Olivetti et al. 2014</xref>). <italic>ARX</italic> is predominantly expressed in the fetal and adult brain, testis, skeletal muscle, and pancreas (<xref ref-type="bibr" rid="TANAKAMCS002097C22">Shoubridge et al. 2010</xref>; <xref ref-type="bibr" rid="TANAKAMCS002097C28">Uhlén et al. 2015</xref>). Patients with pathogenic variants in <italic>ARX</italic> exhibit heterogeneous clinical features resulting in a number of different developmental disorders including Ohtahara (OMIM ID: 308350), Partington (OMIM ID: 309510), and Proud (OMIM ID: 300004) syndromes, X-linked lissencephaly and ambiguous genitalia (XLAG; OMIM ID: 3000215), X-linked infantile spasms syndrome (ISSX; OMIM ID: 308350), and syndromic and nonsyndromic mental retardation (<xref ref-type="bibr" rid="TANAKAMCS002097C22">Shoubridge et al. 2010</xref>; <xref ref-type="bibr" rid="TANAKAMCS002097C19">Olivetti and Noebels 2012</xref>).</p><p>The phenotypes and clinical outcomes of individuals with <italic>ARX</italic>-related disorders resemble those with mutations in <italic>EBF3,</italic> and disruptions in both genes are associated with intellectual disability with various neurological symptoms and are often associated with urogenital malformations. Recent reports of individuals with mutations in <italic>EBF3</italic> have documented genitourinary abnormalities, including several cases of undescended testes as well as micropenis and hypospadias (<xref ref-type="bibr" rid="TANAKAMCS002097C1">Blackburn et al. 2017</xref>; <xref ref-type="bibr" rid="TANAKAMCS002097C3">Chao et al. 2017</xref>; <xref ref-type="bibr" rid="TANAKAMCS002097C15">Harms et al. 2017</xref>; <xref ref-type="bibr" rid="TANAKAMCS002097C24">Sleven et al. 2017</xref>). The male individuals in our study with missense variants, p.Lys64Thr (Patient 1) and p.Arg209Gln (Patient 6), each had a small penis and undescended testes perhaps because of aberrant binding of ARX to <italic>EBF3</italic>, which could result in the disruption of genitourinary patterning during development. It is thus possible that dysregulation of <italic>EBF3</italic> caused by defective binding by ARX may be part of the mechanism leading to the phenotype observed in these patients. Additional studies of <italic>EBF3</italic> are required to elucidate the molecular mechanisms of EBF3-associated neurodevelopmental deficiency and genitourinary abnormalities.</p></sec><sec id="s4" sec-type="methods"><title>METHODS</title><p>Studies were approved by the Institutional Review Board of Columbia University.</p><sec id="s4a"><title>Whole-Exome Sequencing (WES)</title><p>Genomic DNA was extracted from whole blood from the affected children and their parents. Exome sequencing at GeneDx was performed on exon targets captured using the Agilent SureSelect Human All Exon V4 (50 Mb) or the Clinical Research Exome kit (Agilent Technologies) according to the manufacturer's instructions. Libraries were sequenced using the Illumina HiSeq 2000 or 2500 sequencing system with 100-bp paired-end reads (Illumina). Whole-exome sequence data for all sequenced family members was analyzed using GeneDx's XomeAnalyzer (a variant annotation, filtering, and viewing interface for WES data) as described previously (<xref ref-type="table" rid="TANAKAMCS002097TB3">Table 3</xref>; <xref ref-type="bibr" rid="TANAKAMCS002097C25">Tanaka et al. 2016</xref>). Identified sequence variants of interest were confirmed in each proband and both parents by conventional di-deoxy DNA sequence analysis using an ABI3730 (Life Technologies).</p><table-wrap id="TANAKAMCS002097TB3" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Sequencing results</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Patient</th><th align="center" colspan="1" rowspan="1">WES 10× cov</th><th align="center" colspan="1" rowspan="1">Mean cov</th><th align="center" colspan="1" rowspan="1">Kit</th><th align="center" colspan="1" rowspan="1">EBF3 10× cov</th><th align="center" colspan="1" rowspan="1">EBF3 mean CDS cov</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">97.32%</td><td colspan="1" rowspan="1">153</td><td colspan="1" rowspan="1">Agilent CRE</td><td colspan="1" rowspan="1">100.00%</td><td colspan="1" rowspan="1">137</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">92.88%</td><td colspan="1" rowspan="1">47</td><td colspan="1" rowspan="1">Agilent SSv4</td><td colspan="1" rowspan="1">96.77%</td><td colspan="1" rowspan="1">42</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">96.36%</td><td colspan="1" rowspan="1">142</td><td colspan="1" rowspan="1">Agilent SSv4</td><td colspan="1" rowspan="1">100.00%</td><td colspan="1" rowspan="1">118</td></tr><tr><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">91.52%</td><td colspan="1" rowspan="1">103</td><td colspan="1" rowspan="1">Agilent SSv4</td><td colspan="1" rowspan="1">100.00%</td><td colspan="1" rowspan="1">98</td></tr><tr><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">97.00%</td><td colspan="1" rowspan="1">113</td><td colspan="1" rowspan="1">Agilent CRE</td><td colspan="1" rowspan="1">100.00%</td><td colspan="1" rowspan="1">101</td></tr><tr><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">94.85%</td><td colspan="1" rowspan="1">113</td><td colspan="1" rowspan="1">Agilent CRE</td><td colspan="1" rowspan="1">100.00%</td><td colspan="1" rowspan="1">125</td></tr><tr><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">94.69%</td><td colspan="1" rowspan="1">69</td><td colspan="1" rowspan="1">Agilent SSv4</td><td colspan="1" rowspan="1">98.03%</td><td colspan="1" rowspan="1">48</td></tr><tr><td colspan="1" rowspan="1">Mean</td><td colspan="1" rowspan="1">94.95%</td><td colspan="1" rowspan="1">105</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">99.26%</td><td colspan="1" rowspan="1">95</td></tr></tbody></table><table-wrap-foot><fn><p>Results from individuals identified at GeneDx. cov, coverage; CDS, coding sequence.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s4b"><title><italic>EBF3</italic> Primer Sequences</title><list list-type="simple"><list-item><p>Patient 1: Forward ACAGTGTCCAGGAACACGTGA, Reverse CAGGAGGTCTGACCAAGGGC</p></list-item><list-item><p>Patient 2: Forward CATGTTTGGGATTCAGGAGAA, Reverse CCTGCCTCCCGCTTCTA</p></list-item><list-item><p>Patient 3: Forward TAGCCCAGCTCCGAGGGTGA, Reverse CAATCGATGCCCTTCCCGGA</p></list-item><list-item><p>Patient 4: Forward ACCGCTTCATTGTCAGACGT, Reverse TTTTGTTGCTGCTGCGGTTT (This primer set has been discontinued and is not recommended.)</p></list-item><list-item><p>Patient 5: Forward TCTGATAACCCTAATAAATATCAT, Reverse GATTACTTCCTGAACAGTTGC</p></list-item><list-item><p>Patient 6: Forward TCTGATAACCCTAATAAATATCAT, Reverse GATTACTTCCTGAACAGTTGC</p></list-item><list-item><p>Patient 7: Forward GGCGCTAGAGCAGGTGGAAA, Reverse GAGATCACATCGGGCCCGTT</p></list-item></list></sec></sec><sec id="s5"><title>ADDITIONAL INFORMATION</title><sec id="s5a"><title>Data Deposition and Access</title><p>Whole-exome sequencing data are not publicly available because patient consent could not be obtained. The <italic>EBF3</italic> variants found in this study have been deposited in ClinVar (<uri xlink:href="http://www.ncbi.nlm.nih.gov/clinvar">http://www.ncbi.nlm.nih.gov/clinvar</uri>/) under accession numbers SCV000584020.1–SCV000584025.1 and SCV000570295.2.</p></sec><sec id="s5b"><title>Ethics Statement</title><p>The study was approved by the Institutional Review Board of Columbia University. Written informed consent was obtained from the probands or probands’ parents for publication and accompanying images.</p></sec><sec id="s5c"><title>Acknowledgments</title><p>We thank the patients and their families for their generous participation. The Simons Foundation provided funding to W.K.C.</p></sec><sec id="s5d"><title>Author Contributions</title><p>A.J.T. and M.T.C. analyzed the data and drafted and critically reviewed the manuscript. R.W. and M.J.G.S. analyzed the data and critically reviewed the manuscript. K.R. generated and analyzed the data and critically reviewed the manuscript. Y.A.Z., K.B., V.S., K.O., A.W., G.N.W., A.B., T.B.-D., L.O., S.S., M.K.G., I.J.A., and R.E.S. provided the clinical data and critically reviewed the manuscript. W.K.C. conceived of the study, analyzed the data, and drafted and clinically reviewed the manuscript.</p></sec><sec id="s5e"><title>Funding</title><p>This work was supported in part by a grant from the Simons Foundation.</p></sec><sec id="s5f"><title>Competing Interest Statement</title><p>M.C., R.W., K.R., M.G.S., and R.E.S. are employees of GeneDx. W.C. is a former employee of GeneDx and a member of the Scientific Advisory Board of Regeneron Genetics Center.</p></sec></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="PMC_1">
<caption>
<title>Supplemental Material</title>
</caption>
<media mime-subtype="html" mimetype="text" xlink:href="supp_3_6_a002097__index.html"></media>
<media mime-subtype="vnd.ms-excel" mimetype="application" xlink:href="supp_mcs.a002097_Supplemental_Table_S1.xlsx" xlink:role="associated-file"></media>
</supplementary-material>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="supplementary-material">
<p>[Supplemental material is available for this article.]</p>
</fn>
</fn-group>
<ref-list>
<title>REFERENCES</title>
<ref id="TANAKAMCS002097C1">
<mixed-citation publication-type="journal"><name><surname>Blackburn</surname><given-names>PR</given-names></name>, <name><surname>Barnett</surname><given-names>SS</given-names></name>, <name><surname>Zimmerman</surname><given-names>MT</given-names></name>, <name><surname>Cousin</surname><given-names>MA</given-names></name>, <name><surname>Kaiwar</surname><given-names>C</given-names></name>, <name><surname>Pinto E Vairo</surname><given-names>F</given-names></name>, <name><surname>Niu</surname><given-names>Z</given-names></name>, <name><surname>Ferber</surname><given-names>MJ</given-names></name>, <name><surname>Urrutia</surname><given-names>RA</given-names></name>, <name><surname>Selcen</surname><given-names>D</given-names></name>, <etal></etal>
<year>2017</year>
<article-title>Novel de novo variant in <italic>EBF3</italic> is likely to impact DNA binding in a patient with a neurodevelopmental disorder and expanded phenotypes: patient report, in silico functional assessment, and review of published cases</article-title>. <source/>Cold Spring Harb Mol Case Stud
<volume>3</volume>: <fpage>a001743</fpage>.<pub-id pub-id-type="pmid">28487885</pub-id></mixed-citation>
</ref>
<ref id="TANAKAMCS002097C2">
<mixed-citation publication-type="journal"><name><surname>Bu</surname><given-names>W</given-names></name>, <name><surname>Su</surname><given-names>LK</given-names></name>. <year>2003</year>
<article-title>Characterization of functional domains of human EB1 family proteins</article-title>. <source/>J Biol Chem
<volume>278</volume>: <fpage>49721</fpage>–<lpage>49731</lpage>.<pub-id pub-id-type="pmid">14514668</pub-id></mixed-citation>
</ref>
<ref id="TANAKAMCS002097C3">
<mixed-citation publication-type="journal"><name><surname>Chao</surname><given-names>HT</given-names></name>, <name><surname>Davids</surname><given-names>M</given-names></name>, <name><surname>Burke</surname><given-names>E</given-names></name>, <name><surname>Pappas</surname><given-names>JG</given-names></name>, <name><surname>Rosenfeld</surname><given-names>JA</given-names></name>, <name><surname>McCarty</surname><given-names>AJ</given-names></name>, <name><surname>Davis</surname><given-names>T</given-names></name>, <name><surname>Wolfe</surname><given-names>L</given-names></name>, <name><surname>Toro</surname><given-names>C</given-names></name>, <name><surname>Tifft</surname><given-names>C</given-names></name>, <etal></etal>
<year>2017</year>
<article-title>A syndromic neurodevelopmental disorder caused by de novo variants in EBF3</article-title>. <source/>Am J Hum Genet
<volume>100</volume>: <fpage>128</fpage>–<lpage>137</lpage>.<pub-id pub-id-type="pmid">28017372</pub-id></mixed-citation>
</ref>
<ref id="TANAKAMCS002097C4">
<mixed-citation publication-type="journal"><name><surname>Chiara</surname><given-names>F</given-names></name>, <name><surname>Badaloni</surname><given-names>A</given-names></name>, <name><surname>Croci</surname><given-names>L</given-names></name>, <name><surname>Yeh</surname><given-names>ML</given-names></name>, <name><surname>Cariboni</surname><given-names>A</given-names></name>, <name><surname>Hoerder-Suabedissen</surname><given-names>A</given-names></name>, <name><surname>Consalez</surname><given-names>GG</given-names></name>, <name><surname>Eickholt</surname><given-names>B</given-names></name>, <name><surname>Shimogori</surname><given-names>T</given-names></name>, <name><surname>Parnavelas</surname><given-names>JG</given-names></name>, <etal></etal>
<year>2012</year>
<article-title>Early B-cell factors 2 and 3 (EBF2/3) regulate early migration of Cajal–Retzius cells from the cortical hem</article-title>. <source/>Dev Biol
<volume>365</volume>: <fpage>277</fpage>–<lpage>289</lpage>.<pub-id pub-id-type="pmid">22421355</pub-id></mixed-citation>
</ref>
<ref id="TANAKAMCS002097C7">
<mixed-citation publication-type="journal"><name><surname>Cowles</surname><given-names>MW</given-names></name>, <name><surname>Omuro</surname><given-names>KC</given-names></name>, <name><surname>Stanley</surname><given-names>BN</given-names></name>, <name><surname>Quintanilla</surname><given-names>CG</given-names></name>, <name><surname>Zayas</surname><given-names>RM</given-names></name>. <year>2014</year>
<article-title>COE loss-of-function analysis reveals a genetic program underlying maintenance and regeneration of the nervous system in planarians</article-title>. <source/>PLoS Genet
<volume>10</volume>: <fpage>e1004746</fpage>.<pub-id pub-id-type="pmid">25356635</pub-id></mixed-citation>
</ref>
<ref id="TANAKAMCS002097C9">
<mixed-citation publication-type="journal"><name><surname>Daburon</surname><given-names>V</given-names></name>, <name><surname>Mella</surname><given-names>S</given-names></name>, <name><surname>Plouhinec</surname><given-names>JL</given-names></name>, <name><surname>Mazan</surname><given-names>S</given-names></name>, <name><surname>Crozatier</surname><given-names>M</given-names></name>, <name><surname>Vincent</surname><given-names>A</given-names></name>. <year>2008</year>
<article-title>The metazoan history of the COE transcription factors. Selection of a variant HLH motif by mandatory inclusion of a duplicated exon in vertebrates</article-title>. <source/>BMC Evol Biol
<volume>8</volume>: <fpage>131</fpage>.<pub-id pub-id-type="pmid">18454855</pub-id></mixed-citation>
</ref>
<ref id="TANAKAMCS002097C10">
<mixed-citation publication-type="journal"><name><surname>Dubois</surname><given-names>L</given-names></name>, <name><surname>Vincent</surname><given-names>A</given-names></name>. <year>2001</year>
<article-title>The COE—Collier/Olf1/EBF—transcription factors: structural conservation and diversity of developmental functions</article-title>. <source/>Mech Dev
<volume>108</volume>: <fpage>3</fpage>–<lpage>12</lpage>.<pub-id pub-id-type="pmid">11578857</pub-id></mixed-citation>
</ref>
<ref id="TANAKAMCS002097C11">
<mixed-citation publication-type="journal"><name><surname>Faria</surname><given-names>ÁC</given-names></name>, <name><surname>Rabbi-Bortolini</surname><given-names>E</given-names></name>, <name><surname>Rebouças</surname><given-names>MR</given-names></name>, <name><surname>de S Thiago Pereira</surname><given-names>AL</given-names></name>, <name><surname>Frasson</surname><given-names>MG</given-names></name>, <name><surname>Atique</surname><given-names>R</given-names></name>, <name><surname>Lourenço</surname><given-names>NC</given-names></name>, <name><surname>Rosenberg</surname><given-names>C</given-names></name>, <name><surname>Kobayashi</surname><given-names>GS</given-names></name>, <name><surname>Passos-Bueno</surname><given-names>MR</given-names></name>, <etal></etal>
<year>2015</year>
<article-title>Craniosynostosis in 10q26 deletion patients: a consequence of brain underdevelopment or altered suture biology?</article-title>
<source/>Am J Med Genet A
<volume>170A</volume>: <fpage>403</fpage>–<lpage>409</lpage>.<pub-id pub-id-type="pmid">26566760</pub-id></mixed-citation>
</ref>
<ref id="TANAKAMCS002097C12">
<mixed-citation publication-type="journal"><name><surname>Friocourt</surname><given-names>G</given-names></name>, <name><surname>Parnavelas</surname><given-names>JG</given-names></name>. <year>2011</year>
<article-title>Identification of Arx targets unveils new candidates for controlling cortical interneuron migration and differentiation</article-title>. <source/>Front Cell Neurosci
<volume>5</volume>: <fpage>28</fpage>.<pub-id pub-id-type="pmid">22355284</pub-id></mixed-citation>
</ref>
<ref id="TANAKAMCS002097C13">
<mixed-citation publication-type="journal"><name><surname>Fulp</surname><given-names>CT</given-names></name>, <name><surname>Cho</surname><given-names>G</given-names></name>, <name><surname>Marsh</surname><given-names>ED</given-names></name>, <name><surname>Nasrallah</surname><given-names>IM</given-names></name>, <name><surname>Laboskey</surname><given-names>PA</given-names></name>, <name><surname>Golden</surname><given-names>JA</given-names></name>. <year>2008</year>
<article-title>Identification of Arx transcriptional targets in the developing basal forebrain</article-title>. <source/>Hum Mol Genet
<volume>17</volume>: <fpage>3740</fpage>–<lpage>3760</lpage>.<pub-id pub-id-type="pmid">18799476</pub-id></mixed-citation>
</ref>
<ref id="TANAKAMCS002097C14">
<mixed-citation publication-type="journal"><name><surname>Garcia-Dominguez</surname><given-names>M</given-names></name>, <name><surname>Poquet</surname><given-names>C</given-names></name>, <name><surname>Garel</surname><given-names>S</given-names></name>, <name><surname>Charnay</surname><given-names>P</given-names></name>. <year>2003</year>
<article-title><italic>Ebf</italic> gene function is required for coupling neuronal differentiation and cell cycle exit</article-title>. <source/>Development
<volume>130</volume>: <fpage>6013</fpage>–<lpage>6025</lpage>.<pub-id pub-id-type="pmid">14573522</pub-id></mixed-citation>
</ref>
<ref id="TANAKAMCS002097C15">
<mixed-citation publication-type="journal"><name><surname>Harms</surname><given-names>FL</given-names></name>, <name><surname>Girisha</surname><given-names>KM</given-names></name>, <name><surname>Hardigan</surname><given-names>AA</given-names></name>, <name><surname>Kortüm</surname><given-names>F</given-names></name>, <name><surname>Shukla</surname><given-names>A</given-names></name>, <name><surname>Alawi</surname><given-names>M</given-names></name>, <name><surname>Dalal</surname><given-names>A</given-names></name>, <name><surname>Brady</surname><given-names>L</given-names></name>, <name><surname>Tarnopolsky</surname><given-names>M</given-names></name>, <name><surname>Bird</surname><given-names>LM</given-names></name>, <etal></etal>
<year>2017</year>
<article-title>Mutations in <italic>EBF3</italic> disturb transcriptional profiles and cause intellectual disability, ataxia, and facial dysmorphism</article-title>. <source/>Am J Hum Genet
<volume>100</volume>: <fpage>117</fpage>–<lpage>127</lpage>.<pub-id pub-id-type="pmid">28017373</pub-id></mixed-citation>
</ref>
<ref id="TANAKAMCS002097C16">
<mixed-citation publication-type="journal"><name><surname>He</surname><given-names>X</given-names></name>, <name><surname>Sanders</surname><given-names>SJ</given-names></name>, <name><surname>Liu</surname><given-names>L</given-names></name>, <name><surname>De Rubeis</surname><given-names>S</given-names></name>, <name><surname>Lim</surname><given-names>ET</given-names></name>, <name><surname>Sutcliffe</surname><given-names>JS</given-names></name>, <name><surname>Schellenberg</surname><given-names>GD</given-names></name>, <name><surname>Gibbs</surname><given-names>RA</given-names></name>, <name><surname>Daly</surname><given-names>MJ</given-names></name>, <name><surname>Buxbaum</surname><given-names>JD</given-names></name>, <etal></etal>
<year>2013</year>
<article-title>Integrated model of de novo and inherited genetic variants yields greater power to identify risk genes</article-title>. <source/>PLoS Genet
<volume>9</volume>: <fpage>e1003671</fpage>.<pub-id pub-id-type="pmid">23966865</pub-id></mixed-citation>
</ref>
<ref id="TANAKAMCS002097C17">
<mixed-citation publication-type="journal"><name><surname>Jin</surname><given-names>S</given-names></name>, <name><surname>Kim</surname><given-names>J</given-names></name>, <name><surname>Willert</surname><given-names>T</given-names></name>, <name><surname>Klein-Rodewald</surname><given-names>T</given-names></name>, <name><surname>Garcia-Dominguez</surname><given-names>M</given-names></name>, <name><surname>Mosqueira</surname><given-names>M</given-names></name>, <name><surname>Fink</surname><given-names>R</given-names></name>, <name><surname>Esposito</surname><given-names>I</given-names></name>, <name><surname>Hofbauer</surname><given-names>LC</given-names></name>, <name><surname>Charnay</surname><given-names>P</given-names></name>, <etal></etal>
<year>2014</year>
<article-title>Ebf factors and MyoD cooperate to regulate muscle relaxation via <italic>Atp2a1</italic></article-title>. <source/>Nat Commun
<volume>5</volume>: <fpage>3793</fpage>.<pub-id pub-id-type="pmid">24786561</pub-id></mixed-citation>
</ref>
<ref id="TANAKAMCS002097C18">
<mixed-citation publication-type="journal"><name><surname>Liberg</surname><given-names>D</given-names></name>, <name><surname>Sigvardsson</surname><given-names>M</given-names></name>, <name><surname>Akerblad</surname><given-names>P</given-names></name>. <year>2002</year>
<article-title>The EBF/Olf/Collier family of transcription factors: regulators of differentiation in cells originating from all three embryonal germ layers</article-title>. <source/>Mol Cell Biol
<volume>22</volume>: <fpage>8389</fpage>–<lpage>8397</lpage>.<pub-id pub-id-type="pmid">12446759</pub-id></mixed-citation>
</ref>
<ref id="TANAKAMCS002097C19">
<mixed-citation publication-type="journal"><name><surname>Olivetti</surname><given-names>PR</given-names></name>, <name><surname>Noebels</surname><given-names>JL</given-names></name>. <year>2012</year>
<article-title>Interneuron, interrupted: molecular pathogenesis of ARX mutations and X-linked infantile spasms</article-title>. <source/>Curr Opin Neurobiol
<volume>22</volume>: <fpage>859</fpage>–<lpage>865</lpage>.<pub-id pub-id-type="pmid">22565167</pub-id></mixed-citation>
</ref>
<ref id="TANAKAMCS002097C20">
<mixed-citation publication-type="journal"><name><surname>Olivetti</surname><given-names>PR</given-names></name>, <name><surname>Maheshwari</surname><given-names>A</given-names></name>, <name><surname>Noebels</surname><given-names>JL</given-names></name>. <year>2014</year>
<article-title>Neonatal estradiol stimulation prevents epilepsy in Arx model of X-linked infantile spasms syndrome</article-title>. <source/>Sci Transl Med
<volume>6</volume>: <fpage>220ra212</fpage>.</mixed-citation>
</ref>
<ref id="TANAKAMCS002097C21">
<mixed-citation publication-type="journal"><name><surname>Samocha</surname><given-names>KE</given-names></name>, <name><surname>Robinson</surname><given-names>EB</given-names></name>, <name><surname>Sanders</surname><given-names>SJ</given-names></name>, <name><surname>Stevens</surname><given-names>C</given-names></name>, <name><surname>Sabo</surname><given-names>A</given-names></name>, <name><surname>McGrath</surname><given-names>LM</given-names></name>, <name><surname>Kosmicki</surname><given-names>JA</given-names></name>, <name><surname>Rehnström</surname><given-names>K</given-names></name>, <name><surname>Mallick</surname><given-names>S</given-names></name>, <name><surname>Kirby</surname><given-names>A</given-names></name>, <etal></etal>
<year>2014</year>
<article-title>A framework for the interpretation of de novo mutation in human disease</article-title>. <source/>Nat Genet
<volume>46</volume>: <fpage>944</fpage>–<lpage>950</lpage>.<pub-id pub-id-type="pmid">25086666</pub-id></mixed-citation>
</ref>
<ref id="TANAKAMCS002097C22">
<mixed-citation publication-type="journal"><name><surname>Shoubridge</surname><given-names>C</given-names></name>, <name><surname>Fullston</surname><given-names>T</given-names></name>, <name><surname>Gécz</surname><given-names>J</given-names></name>. <year>2010</year>
<article-title>ARX spectrum disorders: making inroads into the molecular pathology</article-title>. <source/>Hum Mutat
<volume>31</volume>: <fpage>889</fpage>–<lpage>900</lpage>.<pub-id pub-id-type="pmid">20506206</pub-id></mixed-citation>
</ref>
<ref id="TANAKAMCS002097C23">
<mixed-citation publication-type="journal"><name><surname>Siponen</surname><given-names>MI</given-names></name>, <name><surname>Wisniewska</surname><given-names>M</given-names></name>, <name><surname>Lehtiö</surname><given-names>L</given-names></name>, <name><surname>Johansson</surname><given-names>I</given-names></name>, <name><surname>Svensson</surname><given-names>L</given-names></name>, <name><surname>Raszewski</surname><given-names>G</given-names></name>, <name><surname>Nilsson</surname><given-names>L</given-names></name>, <name><surname>Sigvardsson</surname><given-names>M</given-names></name>, <name><surname>Berglund</surname><given-names>H</given-names></name>. <year>2010</year>
<article-title>Structural determination of functional domains in early B-cell factor (EBF) family of transcription factors reveals similarities to Rel DNA-binding proteins and a novel dimerization motif</article-title>. <source/>J Biol Chem
<volume>285</volume>: <fpage>25875</fpage>–<lpage>25879</lpage>.<pub-id pub-id-type="pmid">20592035</pub-id></mixed-citation>
</ref>
<ref id="TANAKAMCS002097C24">
<mixed-citation publication-type="journal"><name><surname>Sleven</surname><given-names>H</given-names></name>, <name><surname>Welsh</surname><given-names>SJ</given-names></name>, <name><surname>Yu</surname><given-names>J</given-names></name>, <name><surname>Churchill</surname><given-names>ME</given-names></name>, <name><surname>Wright</surname><given-names>CF</given-names></name>, <name><surname>Henderson</surname><given-names>A</given-names></name>, <name><surname>Horvath</surname><given-names>R</given-names></name>, <name><surname>Rankin</surname><given-names>J</given-names></name>, <name><surname>Vogt</surname><given-names>J</given-names></name>, <name><surname>Magee</surname><given-names>A</given-names></name>, <etal></etal>
<year>2017</year>
<article-title>De novo mutations in <italic>EBF3</italic> cause a neurodevelopmental syndrome</article-title>. <source/>Am J Hum Genet
<volume>100</volume>: <fpage>138</fpage>–<lpage>150</lpage>.<pub-id pub-id-type="pmid">28017370</pub-id></mixed-citation>
</ref>
<ref id="TANAKAMCS002097C25">
<mixed-citation publication-type="journal"><name><surname>Tanaka</surname><given-names>AJ</given-names></name>, <name><surname>Cho</surname><given-names>MT</given-names></name>, <name><surname>Retterer</surname><given-names>K</given-names></name>, <name><surname>Jones</surname><given-names>JR</given-names></name>, <name><surname>Nowak</surname><given-names>C</given-names></name>, <name><surname>Douglas</surname><given-names>J</given-names></name>, <name><surname>Jiang</surname><given-names>YH</given-names></name>, <name><surname>McConkie-Rosell</surname><given-names>A</given-names></name>, <name><surname>Schaefer</surname><given-names>GB</given-names></name>, <name><surname>Kaylor</surname><given-names>J</given-names></name>, <etal></etal>
<year>2016</year>
<article-title>De novo pathogenic variants in <italic>CHAMP1</italic> are associated with global developmental delay, intellectual disability, and dysmorphic facial features</article-title>. <source/>Cold Spring Harb Mol Case Stud
<volume>2</volume>: <fpage>a000661</fpage>.<pub-id pub-id-type="pmid">27148580</pub-id></mixed-citation>
</ref>
<ref id="TANAKAMCS002097C26">
<mixed-citation publication-type="journal"><name><surname>Tao</surname><given-names>YF</given-names></name>, <name><surname>Xu</surname><given-names>LX</given-names></name>, <name><surname>Lu</surname><given-names>J</given-names></name>, <name><surname>Hu</surname><given-names>SY</given-names></name>, <name><surname>Fang</surname><given-names>F</given-names></name>, <name><surname>Cao</surname><given-names>L</given-names></name>, <name><surname>Xiao</surname><given-names>PF</given-names></name>, <name><surname>Du</surname><given-names>XJ</given-names></name>, <name><surname>Sun</surname><given-names>LC</given-names></name>, <name><surname>Li</surname><given-names>ZH</given-names></name>, <etal></etal>
<year>2015</year>
<article-title><italic>Early B-cell factor 3</italic> (<italic>EBF3</italic>) is a novel tumor suppressor gene with promoter hyperrmethylation in pediatric acute myeloid leukemia</article-title>. <source/>J Exp Clin Cancer Res
<volume>34</volume>: <fpage>4</fpage>.<pub-id pub-id-type="pmid">25609158</pub-id></mixed-citation>
</ref>
<ref id="TANAKAMCS002097C27">
<mixed-citation publication-type="journal"><name><surname>Thuret</surname><given-names>S</given-names></name>, <name><surname>Bhatt</surname><given-names>L</given-names></name>, <name><surname>O'Leary</surname><given-names>DD</given-names></name>, <name><surname>Simon</surname><given-names>HH</given-names></name>. <year>2004</year>
<article-title>Identification and developmental analysis of genes expressed by dopaminergic neurons of the substantia nigra pars compacta</article-title>. <source/>Mol Cell Neurosci
<volume>25</volume>: <fpage>394</fpage>–<lpage>405</lpage>.<pub-id pub-id-type="pmid">15033168</pub-id></mixed-citation>
</ref>
<ref id="TANAKAMCS002097C28">
<mixed-citation publication-type="journal"><name><surname>Uhlén</surname><given-names>M</given-names></name>, <name><surname>Fagerberg</surname><given-names>L</given-names></name>, <name><surname>Hallström</surname><given-names>BM</given-names></name>, <name><surname>Lindskog</surname><given-names>C</given-names></name>, <name><surname>Oksvold</surname><given-names>P</given-names></name>, <name><surname>Mardinoglu</surname><given-names>A</given-names></name>, <name><surname>Sivertsson</surname><given-names>Å</given-names></name>, <name><surname>Kampf</surname><given-names>C</given-names></name>, <name><surname>Sjöstedt</surname><given-names>E</given-names></name>, <name><surname>Asplund</surname><given-names>A</given-names></name>, <etal></etal>
<year>2015</year>
<article-title>Proteomics. Tissue-based map of the human proteome</article-title>. <source/>Science
<volume>347</volume>: <fpage>1260419</fpage>.<pub-id pub-id-type="pmid">25613900</pub-id></mixed-citation>
</ref>
<ref id="TANAKAMCS002097C29">
<mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>SS</given-names></name>, <name><surname>Lewcock</surname><given-names>JW</given-names></name>, <name><surname>Feinstein</surname><given-names>P</given-names></name>, <name><surname>Mombaerts</surname><given-names>P</given-names></name>, <name><surname>Reed</surname><given-names>RR</given-names></name>. <year>2004</year>
<article-title>Genetic disruptions of O/E2 and O/E3 genes reveal involvement in olfactory receptor neuron projection</article-title>. <source/>Development
<volume>131</volume>: <fpage>1377</fpage>–<lpage>1388</lpage>.<pub-id pub-id-type="pmid">14993187</pub-id></mixed-citation>
</ref>
<ref id="TANAKAMCS002097C30">
<mixed-citation publication-type="journal"><name><surname>Zhao</surname><given-names>LY</given-names></name>, <name><surname>Niu</surname><given-names>Y</given-names></name>, <name><surname>Santiago</surname><given-names>A</given-names></name>, <name><surname>Liu</surname><given-names>J</given-names></name>, <name><surname>Albert</surname><given-names>SH</given-names></name>, <name><surname>Robertson</surname><given-names>KD</given-names></name>, <name><surname>Liao</surname><given-names>D</given-names></name>. <year>2006</year>
<article-title>An EBF3-mediated transcriptional program that induces cell cycle arrest and apoptosis</article-title>. <source/>Cancer Res
<volume>66</volume>: <fpage>9445</fpage>–<lpage>9452</lpage>.<pub-id pub-id-type="pmid">17018599</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>